Clinical Trial Detail

NCT ID NCT01327612
Title Open Label Extension Study of Conatumumab and AMG 479
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Amgen
Indications

colorectal cancer

sarcoma

lymphoma

Advanced Solid Tumor

non-small cell lung carcinoma

Therapies

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Ganitumab

Bevacizumab

Conatumumab

Age Groups: adult

No variant requirements are available.